Matched Paired Pharmacodynamics and Feasibility Study of Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer

Trial Profile

Matched Paired Pharmacodynamics and Feasibility Study of Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Carboplatin; Paclitaxel
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Jul 2016 Planned primary completion date changed from 1 Aug 2019 to 1 Jul 2019.
    • 05 Jul 2016 Status changed from not yet recruiting to recruiting.
    • 10 May 2016 Planned primary completion date changed from 1 Dec 2018 to 1 Aug 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top